News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG Announces 2016 Third Quarter and Nine Months Financial Results and Reports on Operational Highlights

PDF Revenue increased by 83% in Q3 2016 over same period the prior year Full-year 2016 revenue guidance tightened to EUR 3.5m to EUR 5.0m Epigenomics signs exclusive distribution agreement for Epi proColon in South-East Asia Financial position improved by raising EUR 5.0 million in a private placement to UChip Technology Ltd, a subsidiary of […]

Read more

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that ARUP Laboratories (Salt Lake City, Utah) is the next major U.S. laboratory to offer Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer screening. “I am excited about the inclusion of our […]

Read more

Epigenomics AG: Journal of the American Medical Association (JAMA) publishes “letter to the editor” that clarifies clinical performance data for Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), October 26, 2016 – The Journal of the American Medical Association (JAMA) published a “letter to the editor” discussing the importance of participation and clarifying clinical performance data for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening. In June 2016, JAMA had published […]

Read more

Congressman Donald M. Payne, Jr. Introduces Bipartisan 2016 Colorectal Cancer Detection Act

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and Germantown, MD (U.S.A.), September 29, 2016 – Congressman Donald M. Payne, Jr. (D-NJ), today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act of 2016” at a panel discussion held in Washington D.C. The […]

Read more

Epigenomics AG Announces 2016 Second Quarter and Six Months Financial Results and Reports on Operational Highlights

PDF Revenue increased by 159% in Q2 2016 over same period the prior year Epi proColon® successfully introduced into U.S. market – Leading U.S. laboratory network LabCorp® offers test nationwide Growing momentum in Epi proColon® roll-out as number of ordering U.S. laboratories increases Financial position improved by raising EUR 6.8 million in a private placement […]

Read more

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO)

PDF Gregory Hamilton has a proven track-record of successfully leading U.S. diagnostics companies Appointment underscores Epigenomics’ ambitions and goals in the U.S. market New CEO to join Epigenomics on July 1, 2016 Berlin (Germany) and Germantown, MD (U.S.A.), June 30, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, […]

Read more
......